title: Targeting the inhibitor of Apoptosis Protein BIR3 binding domains.
abstract: The Inhibitor of Apoptosis Proteins (IAPs) play a critical role in the regulation of cellular apoptosis and cytokine signaling. IAP family members include XIAP, cIAP1, cIAP2, NAIP, survivin, Apollon/Bruce, ML-IAP/livin and TIAP. The IAPs have been targeted using both antisense oligonucleotides and small molecule inhibitors. Several research teams have advanced compounds that bind the highly conserved BIR3 domains of the IAPs into clinical trials, as single agents and in combination with standard of care. This patent review highlights the medicinal chemistry strategies that have been applied to the development of clinical compounds.
authors.affiliation: JAQJAM Consulting, Vancouver, British Columbia, Canada.
authors.forename: James B
authors.initials: JB
authors.lastname: Jaquith
mesh_terms: D001665:Binding Sites; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D017434:Protein Structure, Tertiary
chemical_list: D051034:Inhibitor of Apoptosis Proteins